Evidence from Checkmate-026 trail has suggested that TMB can identify a subgroup that may benefit from PD-1 inhibitors among NSCLC patients with PD-L1 expression levels ≥5% (Carbone et al., 2017). This evidence concerns the gene CD274 and non-small cell lung carcinoma.